[
    {
        "recordid": "GLY_000310_1_238001",
        "row": "[\"P15498-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238002",
        "row": "[\"P15514-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238003",
        "row": "[\"O15520-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238004",
        "row": "[\"O76093-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238005",
        "row": "[\"P12931-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238006",
        "row": "[\"Q9Y4H2-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238007",
        "row": "[\"Q9GZV9-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238008",
        "row": "[\"P11487-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238009",
        "row": "[\"P10767-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238010",
        "row": "[\"Q92731-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238011",
        "row": "[\"Q99075-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238012",
        "row": "[\"O95750-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238013",
        "row": "[\"O14944-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238014",
        "row": "[\"Q06124-2\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238015",
        "row": "[\"P21781-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238016",
        "row": "[\"P49771-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238017",
        "row": "[\"P03372-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238018",
        "row": "[\"P42338-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238019",
        "row": "[\"P42336-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238020",
        "row": "[\"O14511-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238021",
        "row": "[\"P63000-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238022",
        "row": "[\"Q86Z14-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238023",
        "row": "[\"Q9HCT0-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238024",
        "row": "[\"Q9UQC2-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238025",
        "row": "[\"P00533-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238026",
        "row": "[\"P05230-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238027",
        "row": "[\"Q13480-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238028",
        "row": "[\"P15153-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238029",
        "row": "[\"P01133-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238030",
        "row": "[\"P01135-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238031",
        "row": "[\"P09038-4\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238032",
        "row": "[\"P16234-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238033",
        "row": "[\"P08620-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238034",
        "row": "[\"P14210-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238035",
        "row": "[\"P01127-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238036",
        "row": "[\"P10721-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238037",
        "row": "[\"P35070-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238038",
        "row": "[\"Q8WU20-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238039",
        "row": "[\"Q9NP95-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238040",
        "row": "[\"P33681-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238041",
        "row": "[\"P42081-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238042",
        "row": "[\"O43320-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238043",
        "row": "[\"O00329-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238044",
        "row": "[\"P36888-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238045",
        "row": "[\"P56975-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238046",
        "row": "[\"Q6ZUJ8-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238047",
        "row": "[\"Q6PIZ9-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238048",
        "row": "[\"P15391-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238049",
        "row": "[\"P04626-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238050",
        "row": "[\"P84095-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238051",
        "row": "[\"P27986-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238052",
        "row": "[\"P09619-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238053",
        "row": "[\"Q02297-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238054",
        "row": "[\"O00459-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238055",
        "row": "[\"Q8WWG1-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238056",
        "row": "[\"P22455-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238057",
        "row": "[\"P06241-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238058",
        "row": "[\"P31371-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238059",
        "row": "[\"Q92569-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238060",
        "row": "[\"P06239-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238061",
        "row": "[\"P10747-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238062",
        "row": "[\"O43815-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238063",
        "row": "[\"P08581-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238064",
        "row": "[\"Q6UW88-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238065",
        "row": "[\"P35568-1\", \"Targeting the phosphoinositide 3-kinase pathway in cancer.\", \"Nature reviews. Drug discovery\", \"2009 Aug\", \"Liu P, Cheng H, Roberts TM, Zhao JJ\", \"protein_xref_pubmed\", \"19644473\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238066",
        "row": "[\"P15498-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238067",
        "row": "[\"P15514-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238068",
        "row": "[\"O15520-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238069",
        "row": "[\"O76093-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238070",
        "row": "[\"P12931-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238071",
        "row": "[\"Q9Y4H2-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238072",
        "row": "[\"Q9GZV9-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238073",
        "row": "[\"P11487-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238074",
        "row": "[\"P10767-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238075",
        "row": "[\"Q92731-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238076",
        "row": "[\"Q99075-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238077",
        "row": "[\"O95750-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238078",
        "row": "[\"O14944-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238079",
        "row": "[\"Q06124-2\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238080",
        "row": "[\"P21781-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238081",
        "row": "[\"P49771-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238082",
        "row": "[\"P03372-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238083",
        "row": "[\"P42338-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238084",
        "row": "[\"P42336-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238085",
        "row": "[\"O14511-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238086",
        "row": "[\"P63000-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238087",
        "row": "[\"Q86Z14-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238088",
        "row": "[\"Q9HCT0-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238089",
        "row": "[\"Q9UQC2-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238090",
        "row": "[\"P00533-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238091",
        "row": "[\"P05230-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238092",
        "row": "[\"Q13480-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238093",
        "row": "[\"P15153-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238094",
        "row": "[\"P01133-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238095",
        "row": "[\"P01135-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238096",
        "row": "[\"P09038-4\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238097",
        "row": "[\"P16234-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238098",
        "row": "[\"P08620-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238099",
        "row": "[\"P14210-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238100",
        "row": "[\"P01127-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238101",
        "row": "[\"P10721-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238102",
        "row": "[\"P35070-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238103",
        "row": "[\"Q8WU20-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238104",
        "row": "[\"Q9NP95-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238105",
        "row": "[\"P33681-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238106",
        "row": "[\"P42081-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238107",
        "row": "[\"O43320-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238108",
        "row": "[\"O00329-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238109",
        "row": "[\"P36888-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238110",
        "row": "[\"P56975-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238111",
        "row": "[\"Q6ZUJ8-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238112",
        "row": "[\"Q6PIZ9-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238113",
        "row": "[\"P15391-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238114",
        "row": "[\"P04626-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238115",
        "row": "[\"P84095-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238116",
        "row": "[\"P27986-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238117",
        "row": "[\"P09619-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238118",
        "row": "[\"Q02297-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238119",
        "row": "[\"O00459-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238120",
        "row": "[\"Q8WWG1-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238121",
        "row": "[\"P22455-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238122",
        "row": "[\"P06241-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238123",
        "row": "[\"P31371-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238124",
        "row": "[\"Q92569-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238125",
        "row": "[\"P06239-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238126",
        "row": "[\"P10747-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238127",
        "row": "[\"O43815-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238128",
        "row": "[\"P08581-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238129",
        "row": "[\"Q6UW88-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238130",
        "row": "[\"P35568-1\", \"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.\", \"Cancer cell\", \"2009 Dec 8\", \"Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S\", \"protein_xref_pubmed\", \"19962665\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238131",
        "row": "[\"P15498-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238132",
        "row": "[\"P15514-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238133",
        "row": "[\"O15520-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238134",
        "row": "[\"O76093-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238135",
        "row": "[\"P12931-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238136",
        "row": "[\"Q9Y4H2-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238137",
        "row": "[\"Q9GZV9-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238138",
        "row": "[\"P11487-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238139",
        "row": "[\"P10767-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238140",
        "row": "[\"Q92731-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238141",
        "row": "[\"Q99075-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238142",
        "row": "[\"O95750-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238143",
        "row": "[\"O14944-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238144",
        "row": "[\"Q06124-2\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238145",
        "row": "[\"P21781-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238146",
        "row": "[\"P49771-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238147",
        "row": "[\"P03372-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238148",
        "row": "[\"P42338-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238149",
        "row": "[\"P42336-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238150",
        "row": "[\"O14511-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238151",
        "row": "[\"P63000-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238152",
        "row": "[\"Q86Z14-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238153",
        "row": "[\"Q9HCT0-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238154",
        "row": "[\"Q9UQC2-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238155",
        "row": "[\"P00533-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238156",
        "row": "[\"P05230-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238157",
        "row": "[\"Q13480-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238158",
        "row": "[\"P15153-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238159",
        "row": "[\"P01133-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238160",
        "row": "[\"P01135-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238161",
        "row": "[\"P09038-4\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238162",
        "row": "[\"P16234-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238163",
        "row": "[\"P08620-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238164",
        "row": "[\"P14210-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238165",
        "row": "[\"P01127-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238166",
        "row": "[\"P10721-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238167",
        "row": "[\"P35070-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238168",
        "row": "[\"Q8WU20-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238169",
        "row": "[\"Q9NP95-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238170",
        "row": "[\"P33681-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238171",
        "row": "[\"P42081-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238172",
        "row": "[\"O43320-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238173",
        "row": "[\"O00329-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238174",
        "row": "[\"P36888-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238175",
        "row": "[\"P56975-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238176",
        "row": "[\"Q6ZUJ8-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238177",
        "row": "[\"Q6PIZ9-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238178",
        "row": "[\"P15391-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238179",
        "row": "[\"P04626-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238180",
        "row": "[\"P84095-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238181",
        "row": "[\"P27986-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238182",
        "row": "[\"P09619-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238183",
        "row": "[\"Q02297-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238184",
        "row": "[\"O00459-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238185",
        "row": "[\"Q8WWG1-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238186",
        "row": "[\"P22455-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238187",
        "row": "[\"P06241-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238188",
        "row": "[\"P31371-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238189",
        "row": "[\"Q92569-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238190",
        "row": "[\"P06239-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238191",
        "row": "[\"P10747-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238192",
        "row": "[\"O43815-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238193",
        "row": "[\"P08581-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238194",
        "row": "[\"Q6UW88-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238195",
        "row": "[\"P35568-1\", \"Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.\", \"The Journal of biological chemistry\", \"2010 May 14\", \"Jiang X, Chen S, Asara JM, Balk SP\", \"protein_xref_pubmed\", \"20231295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238196",
        "row": "[\"P15498-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238197",
        "row": "[\"P15514-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238198",
        "row": "[\"O15520-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238199",
        "row": "[\"O76093-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238200",
        "row": "[\"P12931-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238201",
        "row": "[\"Q9Y4H2-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238202",
        "row": "[\"Q9GZV9-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238203",
        "row": "[\"P11487-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238204",
        "row": "[\"P10767-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238205",
        "row": "[\"Q92731-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238206",
        "row": "[\"Q99075-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238207",
        "row": "[\"O95750-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238208",
        "row": "[\"O14944-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238209",
        "row": "[\"Q06124-2\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238210",
        "row": "[\"P21781-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238211",
        "row": "[\"P49771-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238212",
        "row": "[\"P03372-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238213",
        "row": "[\"P42338-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238214",
        "row": "[\"P42336-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238215",
        "row": "[\"O14511-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238216",
        "row": "[\"P63000-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238217",
        "row": "[\"Q86Z14-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238218",
        "row": "[\"Q9HCT0-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238219",
        "row": "[\"Q9UQC2-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238220",
        "row": "[\"P00533-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238221",
        "row": "[\"P05230-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238222",
        "row": "[\"Q13480-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238223",
        "row": "[\"P15153-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238224",
        "row": "[\"P01133-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238225",
        "row": "[\"P01135-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238226",
        "row": "[\"P09038-4\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238227",
        "row": "[\"P16234-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238228",
        "row": "[\"P08620-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238229",
        "row": "[\"P14210-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238230",
        "row": "[\"P01127-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238231",
        "row": "[\"P10721-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238232",
        "row": "[\"P35070-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238233",
        "row": "[\"Q8WU20-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238234",
        "row": "[\"Q9NP95-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238235",
        "row": "[\"P33681-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238236",
        "row": "[\"P42081-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238237",
        "row": "[\"O43320-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238238",
        "row": "[\"O00329-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238239",
        "row": "[\"P36888-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238240",
        "row": "[\"P56975-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238241",
        "row": "[\"Q6ZUJ8-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238242",
        "row": "[\"Q6PIZ9-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238243",
        "row": "[\"P15391-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238244",
        "row": "[\"P04626-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238245",
        "row": "[\"P84095-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238246",
        "row": "[\"P27986-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238247",
        "row": "[\"P09619-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238248",
        "row": "[\"Q02297-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238249",
        "row": "[\"O00459-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238250",
        "row": "[\"Q8WWG1-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238251",
        "row": "[\"P22455-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238252",
        "row": "[\"P06241-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238253",
        "row": "[\"P31371-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238254",
        "row": "[\"Q92569-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238255",
        "row": "[\"P06239-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238256",
        "row": "[\"P10747-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238257",
        "row": "[\"O43815-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238258",
        "row": "[\"P08581-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238259",
        "row": "[\"Q6UW88-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238260",
        "row": "[\"P35568-1\", \"Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.\", \"Proceedings of the National Academy of Sciences of the United States of America\", \"2010 Aug 31\", \"Sun M, Hillmann P, Hofmann BT, Hart JR, Vogt PK\", \"protein_xref_pubmed\", \"20713702\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238261",
        "row": "[\"P15498-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238262",
        "row": "[\"P15514-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238263",
        "row": "[\"O15520-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238264",
        "row": "[\"O76093-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238265",
        "row": "[\"P12931-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238266",
        "row": "[\"Q9Y4H2-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238267",
        "row": "[\"Q9GZV9-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238268",
        "row": "[\"P11487-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238269",
        "row": "[\"P10767-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238270",
        "row": "[\"Q92731-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238271",
        "row": "[\"Q99075-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238272",
        "row": "[\"O95750-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238273",
        "row": "[\"O14944-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238274",
        "row": "[\"Q06124-2\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238275",
        "row": "[\"P21781-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238276",
        "row": "[\"P49771-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238277",
        "row": "[\"P03372-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238278",
        "row": "[\"P42338-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238279",
        "row": "[\"P42336-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238280",
        "row": "[\"O14511-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238281",
        "row": "[\"P63000-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238282",
        "row": "[\"Q86Z14-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238283",
        "row": "[\"Q9HCT0-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238284",
        "row": "[\"Q9UQC2-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238285",
        "row": "[\"P00533-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238286",
        "row": "[\"P05230-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238287",
        "row": "[\"Q13480-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238288",
        "row": "[\"P15153-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238289",
        "row": "[\"P01133-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238290",
        "row": "[\"P01135-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238291",
        "row": "[\"P09038-4\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238292",
        "row": "[\"P16234-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238293",
        "row": "[\"P08620-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238294",
        "row": "[\"P14210-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238295",
        "row": "[\"P01127-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238296",
        "row": "[\"P10721-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238297",
        "row": "[\"P35070-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238298",
        "row": "[\"Q8WU20-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238299",
        "row": "[\"Q9NP95-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238300",
        "row": "[\"P33681-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238301",
        "row": "[\"P42081-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238302",
        "row": "[\"O43320-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238303",
        "row": "[\"O00329-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238304",
        "row": "[\"P36888-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238305",
        "row": "[\"P56975-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238306",
        "row": "[\"Q6ZUJ8-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238307",
        "row": "[\"Q6PIZ9-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238308",
        "row": "[\"P15391-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238309",
        "row": "[\"P04626-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238310",
        "row": "[\"P84095-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238311",
        "row": "[\"P27986-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238312",
        "row": "[\"P09619-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238313",
        "row": "[\"Q02297-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238314",
        "row": "[\"O00459-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238315",
        "row": "[\"Q8WWG1-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238316",
        "row": "[\"P22455-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238317",
        "row": "[\"P06241-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238318",
        "row": "[\"P31371-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238319",
        "row": "[\"Q92569-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238320",
        "row": "[\"P06239-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238321",
        "row": "[\"P10747-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238322",
        "row": "[\"O43815-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238323",
        "row": "[\"P08581-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238324",
        "row": "[\"Q6UW88-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238325",
        "row": "[\"P35568-1\", \"PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts.\", \"Journal of neuro-oncology\", \"2011 Aug\", \"Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L\", \"protein_xref_pubmed\", \"21188471\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238326",
        "row": "[\"P15498-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238327",
        "row": "[\"P15514-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238328",
        "row": "[\"O15520-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238329",
        "row": "[\"O76093-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238330",
        "row": "[\"P12931-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238331",
        "row": "[\"Q9Y4H2-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238332",
        "row": "[\"Q9GZV9-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238333",
        "row": "[\"P11487-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238334",
        "row": "[\"P10767-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238335",
        "row": "[\"Q92731-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238336",
        "row": "[\"Q99075-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238337",
        "row": "[\"O95750-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238338",
        "row": "[\"O14944-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238339",
        "row": "[\"Q06124-2\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238340",
        "row": "[\"P21781-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238341",
        "row": "[\"P49771-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238342",
        "row": "[\"P03372-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238343",
        "row": "[\"P42338-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238344",
        "row": "[\"P42336-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238345",
        "row": "[\"O14511-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238346",
        "row": "[\"P63000-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238347",
        "row": "[\"Q86Z14-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238348",
        "row": "[\"Q9HCT0-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238349",
        "row": "[\"Q9UQC2-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238350",
        "row": "[\"P00533-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238351",
        "row": "[\"P05230-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238352",
        "row": "[\"Q13480-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238353",
        "row": "[\"P15153-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238354",
        "row": "[\"P01133-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238355",
        "row": "[\"P01135-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238356",
        "row": "[\"P09038-4\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238357",
        "row": "[\"P16234-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238358",
        "row": "[\"P08620-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238359",
        "row": "[\"P14210-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238360",
        "row": "[\"P01127-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238361",
        "row": "[\"P10721-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238362",
        "row": "[\"P35070-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238363",
        "row": "[\"Q8WU20-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238364",
        "row": "[\"Q9NP95-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238365",
        "row": "[\"P33681-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238366",
        "row": "[\"P42081-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238367",
        "row": "[\"O43320-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238368",
        "row": "[\"O00329-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238369",
        "row": "[\"P36888-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238370",
        "row": "[\"P56975-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238371",
        "row": "[\"Q6ZUJ8-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238372",
        "row": "[\"Q6PIZ9-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238373",
        "row": "[\"P15391-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238374",
        "row": "[\"P04626-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238375",
        "row": "[\"P84095-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238376",
        "row": "[\"P27986-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238377",
        "row": "[\"P09619-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238378",
        "row": "[\"Q02297-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238379",
        "row": "[\"O00459-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238380",
        "row": "[\"Q8WWG1-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238381",
        "row": "[\"P22455-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238382",
        "row": "[\"P06241-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238383",
        "row": "[\"P31371-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238384",
        "row": "[\"Q92569-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238385",
        "row": "[\"P06239-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238386",
        "row": "[\"P10747-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238387",
        "row": "[\"O43815-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238388",
        "row": "[\"P08581-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238389",
        "row": "[\"Q6UW88-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238390",
        "row": "[\"P35568-1\", \"PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer.\", \"Cancer research\", \"2011 Jun 15\", \"Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW\", \"protein_xref_pubmed\", \"21478295\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238391",
        "row": "[\"P15498-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238392",
        "row": "[\"P15514-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238393",
        "row": "[\"O15520-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238394",
        "row": "[\"O76093-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238395",
        "row": "[\"P12931-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238396",
        "row": "[\"Q9Y4H2-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238397",
        "row": "[\"Q9GZV9-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238398",
        "row": "[\"P11487-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238399",
        "row": "[\"P10767-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238400",
        "row": "[\"Q92731-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238401",
        "row": "[\"Q99075-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238402",
        "row": "[\"O95750-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238403",
        "row": "[\"O14944-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238404",
        "row": "[\"Q06124-2\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238405",
        "row": "[\"P21781-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238406",
        "row": "[\"P49771-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238407",
        "row": "[\"P03372-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238408",
        "row": "[\"P42338-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238409",
        "row": "[\"P42336-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238410",
        "row": "[\"O14511-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238411",
        "row": "[\"P63000-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238412",
        "row": "[\"Q86Z14-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238413",
        "row": "[\"Q9HCT0-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238414",
        "row": "[\"Q9UQC2-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238415",
        "row": "[\"P00533-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238416",
        "row": "[\"P05230-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238417",
        "row": "[\"Q13480-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238418",
        "row": "[\"P15153-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238419",
        "row": "[\"P01133-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238420",
        "row": "[\"P01135-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238421",
        "row": "[\"P09038-4\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238422",
        "row": "[\"P16234-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238423",
        "row": "[\"P08620-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238424",
        "row": "[\"P14210-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238425",
        "row": "[\"P01127-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238426",
        "row": "[\"P10721-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238427",
        "row": "[\"P35070-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238428",
        "row": "[\"Q8WU20-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238429",
        "row": "[\"Q9NP95-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238430",
        "row": "[\"P33681-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238431",
        "row": "[\"P42081-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238432",
        "row": "[\"O43320-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238433",
        "row": "[\"O00329-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238434",
        "row": "[\"P36888-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238435",
        "row": "[\"P56975-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238436",
        "row": "[\"Q6ZUJ8-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238437",
        "row": "[\"Q6PIZ9-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238438",
        "row": "[\"P15391-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238439",
        "row": "[\"P04626-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238440",
        "row": "[\"P84095-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238441",
        "row": "[\"P27986-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238442",
        "row": "[\"P09619-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238443",
        "row": "[\"Q02297-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238444",
        "row": "[\"O00459-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238445",
        "row": "[\"Q8WWG1-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238446",
        "row": "[\"P22455-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238447",
        "row": "[\"P06241-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238448",
        "row": "[\"P31371-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238449",
        "row": "[\"Q92569-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238450",
        "row": "[\"P06239-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238451",
        "row": "[\"P10747-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238452",
        "row": "[\"O43815-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238453",
        "row": "[\"P08581-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238454",
        "row": "[\"Q6UW88-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238455",
        "row": "[\"P35568-1\", \"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.\", \"Cancer discovery\", \"2011 Jul\", \"Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB\", \"protein_xref_pubmed\", \"21984976\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238456",
        "row": "[\"P15498-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238457",
        "row": "[\"P15514-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238458",
        "row": "[\"O15520-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238459",
        "row": "[\"O76093-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238460",
        "row": "[\"P12931-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238461",
        "row": "[\"Q9Y4H2-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238462",
        "row": "[\"Q9GZV9-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238463",
        "row": "[\"P11487-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238464",
        "row": "[\"P10767-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238465",
        "row": "[\"Q92731-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238466",
        "row": "[\"Q99075-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238467",
        "row": "[\"O95750-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238468",
        "row": "[\"O14944-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238469",
        "row": "[\"Q06124-2\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238470",
        "row": "[\"P21781-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238471",
        "row": "[\"P49771-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238472",
        "row": "[\"P03372-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238473",
        "row": "[\"P42338-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238474",
        "row": "[\"P42336-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238475",
        "row": "[\"O14511-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238476",
        "row": "[\"P63000-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238477",
        "row": "[\"Q86Z14-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238478",
        "row": "[\"Q9HCT0-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238479",
        "row": "[\"Q9UQC2-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238480",
        "row": "[\"P00533-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238481",
        "row": "[\"P05230-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238482",
        "row": "[\"Q13480-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238483",
        "row": "[\"P15153-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238484",
        "row": "[\"P01133-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238485",
        "row": "[\"P01135-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238486",
        "row": "[\"P09038-4\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238487",
        "row": "[\"P16234-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238488",
        "row": "[\"P08620-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238489",
        "row": "[\"P14210-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238490",
        "row": "[\"P01127-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238491",
        "row": "[\"P10721-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238492",
        "row": "[\"P35070-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238493",
        "row": "[\"Q8WU20-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238494",
        "row": "[\"Q9NP95-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238495",
        "row": "[\"P33681-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238496",
        "row": "[\"P42081-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238497",
        "row": "[\"O43320-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238498",
        "row": "[\"O00329-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238499",
        "row": "[\"P36888-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238500",
        "row": "[\"P56975-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238501",
        "row": "[\"Q6ZUJ8-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238502",
        "row": "[\"Q6PIZ9-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238503",
        "row": "[\"P15391-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238504",
        "row": "[\"P04626-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238505",
        "row": "[\"P84095-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238506",
        "row": "[\"P27986-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238507",
        "row": "[\"P09619-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238508",
        "row": "[\"Q02297-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238509",
        "row": "[\"O00459-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238510",
        "row": "[\"Q8WWG1-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238511",
        "row": "[\"P22455-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238512",
        "row": "[\"P06241-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238513",
        "row": "[\"P31371-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238514",
        "row": "[\"Q92569-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238515",
        "row": "[\"P06239-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238516",
        "row": "[\"P10747-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238517",
        "row": "[\"O43815-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238518",
        "row": "[\"P08581-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238519",
        "row": "[\"Q6UW88-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238520",
        "row": "[\"P35568-1\", \"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.\", \"Oncogene\", \"2012 Aug 9\", \"Hon WC, Berndt A, Williams RL\", \"protein_xref_pubmed\", \"22120714\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238521",
        "row": "[\"P07942-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238522",
        "row": "[\"P02458-2\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238523",
        "row": "[\"P02452-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238524",
        "row": "[\"P13942-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238525",
        "row": "[\"P29400-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238526",
        "row": "[\"Q9Y6N6-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238527",
        "row": "[\"Q16832-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238528",
        "row": "[\"P20908-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238529",
        "row": "[\"P02462-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238530",
        "row": "[\"P02461-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238531",
        "row": "[\"Q01955-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238532",
        "row": "[\"Q13751-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238533",
        "row": "[\"Q13753-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238534",
        "row": "[\"Q14031-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238535",
        "row": "[\"P98160-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238536",
        "row": "[\"P02751-15\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238537",
        "row": "[\"P09038-4\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238538",
        "row": "[\"Q14118-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238539",
        "row": "[\"Q08345-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238540",
        "row": "[\"P01127-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238541",
        "row": "[\"P02766-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238542",
        "row": "[\"P53420-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238543",
        "row": "[\"Q16363-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238544",
        "row": "[\"P05997-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238545",
        "row": "[\"P12107-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238546",
        "row": "[\"O15230-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238547",
        "row": "[\"P25391-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238548",
        "row": "[\"P55268-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238549",
        "row": "[\"Q16787-2\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238550",
        "row": "[\"Q9ULB1-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238551",
        "row": "[\"Q03692-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238552",
        "row": "[\"P11047-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238553",
        "row": "[\"P04085-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238554",
        "row": "[\"P11532-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238555",
        "row": "[\"P24043-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238556",
        "row": "[\"P08572-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238557",
        "row": "[\"P25940-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238558",
        "row": "[\"O00468-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238559",
        "row": "[\"P08123-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238560",
        "row": "[\"Q9HB63-1\", \"Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.\", \"The Journal of biological chemistry\", \"2002 Apr 26\", \"Knox S, Merry C, Stringer S, Melrose J, Whitelock J\", \"protein_xref_pubmed\", \"11847221\", \"protein_xref_reactome\", \"R-HSA-3000171\"]"
    },
    {
        "recordid": "GLY_000310_1_238561",
        "row": "[\"P15498-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238562",
        "row": "[\"P15514-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238563",
        "row": "[\"O15520-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238564",
        "row": "[\"O76093-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238565",
        "row": "[\"P12931-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238566",
        "row": "[\"Q9Y4H2-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238567",
        "row": "[\"Q9GZV9-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238568",
        "row": "[\"P11487-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238569",
        "row": "[\"P10767-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238570",
        "row": "[\"Q92731-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238571",
        "row": "[\"Q99075-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238572",
        "row": "[\"O95750-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238573",
        "row": "[\"O14944-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238574",
        "row": "[\"Q06124-2\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238575",
        "row": "[\"P21781-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238576",
        "row": "[\"P49771-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238577",
        "row": "[\"P03372-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238578",
        "row": "[\"P42338-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238579",
        "row": "[\"P42336-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238580",
        "row": "[\"O14511-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238581",
        "row": "[\"P63000-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238582",
        "row": "[\"Q86Z14-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238583",
        "row": "[\"Q9HCT0-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238584",
        "row": "[\"Q9UQC2-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238585",
        "row": "[\"P00533-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238586",
        "row": "[\"P05230-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238587",
        "row": "[\"Q13480-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238588",
        "row": "[\"P15153-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238589",
        "row": "[\"P01133-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238590",
        "row": "[\"P01135-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238591",
        "row": "[\"P09038-4\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238592",
        "row": "[\"P16234-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238593",
        "row": "[\"P08620-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238594",
        "row": "[\"P14210-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238595",
        "row": "[\"P01127-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238596",
        "row": "[\"P10721-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238597",
        "row": "[\"P35070-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238598",
        "row": "[\"Q8WU20-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238599",
        "row": "[\"Q9NP95-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238600",
        "row": "[\"P33681-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238601",
        "row": "[\"P42081-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238602",
        "row": "[\"O43320-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238603",
        "row": "[\"O00329-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238604",
        "row": "[\"P36888-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238605",
        "row": "[\"P56975-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238606",
        "row": "[\"Q6ZUJ8-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238607",
        "row": "[\"Q6PIZ9-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238608",
        "row": "[\"P15391-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238609",
        "row": "[\"P04626-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238610",
        "row": "[\"P84095-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238611",
        "row": "[\"P27986-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238612",
        "row": "[\"P09619-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238613",
        "row": "[\"Q02297-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238614",
        "row": "[\"O00459-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238615",
        "row": "[\"Q8WWG1-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238616",
        "row": "[\"P22455-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238617",
        "row": "[\"P06241-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238618",
        "row": "[\"P31371-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238619",
        "row": "[\"Q92569-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238620",
        "row": "[\"P06239-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238621",
        "row": "[\"P10747-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238622",
        "row": "[\"O43815-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238623",
        "row": "[\"P08581-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238624",
        "row": "[\"Q6UW88-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238625",
        "row": "[\"P35568-1\", \"PI 3-kinase p110beta: a new target for antithrombotic therapy.\", \"Nature medicine\", \"2005 May\", \"Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH\", \"protein_xref_pubmed\", \"15834429\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238626",
        "row": "[\"P15498-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238627",
        "row": "[\"P15514-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238628",
        "row": "[\"O15520-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238629",
        "row": "[\"O76093-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238630",
        "row": "[\"P12931-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238631",
        "row": "[\"Q9Y4H2-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238632",
        "row": "[\"Q9GZV9-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238633",
        "row": "[\"P11487-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238634",
        "row": "[\"P10767-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238635",
        "row": "[\"Q92731-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238636",
        "row": "[\"Q99075-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238637",
        "row": "[\"O95750-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238638",
        "row": "[\"O14944-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238639",
        "row": "[\"Q06124-2\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238640",
        "row": "[\"P21781-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238641",
        "row": "[\"P49771-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238642",
        "row": "[\"P03372-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238643",
        "row": "[\"P42338-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238644",
        "row": "[\"P42336-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238645",
        "row": "[\"O14511-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238646",
        "row": "[\"P63000-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238647",
        "row": "[\"Q86Z14-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238648",
        "row": "[\"Q9HCT0-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238649",
        "row": "[\"Q9UQC2-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238650",
        "row": "[\"P00533-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238651",
        "row": "[\"P05230-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238652",
        "row": "[\"Q13480-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238653",
        "row": "[\"P15153-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238654",
        "row": "[\"P01133-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238655",
        "row": "[\"P01135-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238656",
        "row": "[\"P09038-4\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238657",
        "row": "[\"P16234-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238658",
        "row": "[\"P08620-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238659",
        "row": "[\"P14210-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238660",
        "row": "[\"P01127-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238661",
        "row": "[\"P10721-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238662",
        "row": "[\"P35070-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238663",
        "row": "[\"Q8WU20-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238664",
        "row": "[\"Q9NP95-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238665",
        "row": "[\"P33681-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238666",
        "row": "[\"P42081-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238667",
        "row": "[\"O43320-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238668",
        "row": "[\"O00329-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238669",
        "row": "[\"P36888-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238670",
        "row": "[\"P56975-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238671",
        "row": "[\"Q6ZUJ8-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238672",
        "row": "[\"Q6PIZ9-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238673",
        "row": "[\"P15391-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238674",
        "row": "[\"P04626-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238675",
        "row": "[\"P84095-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238676",
        "row": "[\"P27986-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238677",
        "row": "[\"P09619-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238678",
        "row": "[\"Q02297-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238679",
        "row": "[\"O00459-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238680",
        "row": "[\"Q8WWG1-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238681",
        "row": "[\"P22455-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238682",
        "row": "[\"P06241-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238683",
        "row": "[\"P31371-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238684",
        "row": "[\"Q92569-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238685",
        "row": "[\"P06239-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238686",
        "row": "[\"P10747-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238687",
        "row": "[\"O43815-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238688",
        "row": "[\"P08581-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238689",
        "row": "[\"Q6UW88-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238690",
        "row": "[\"P35568-1\", \"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.\", \"Cell\", \"2006 May 19\", \"Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM\", \"protein_xref_pubmed\", \"16647110\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238691",
        "row": "[\"P15498-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238692",
        "row": "[\"P15514-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238693",
        "row": "[\"O15520-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238694",
        "row": "[\"O76093-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238695",
        "row": "[\"P12931-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238696",
        "row": "[\"Q9Y4H2-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238697",
        "row": "[\"Q9GZV9-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238698",
        "row": "[\"P11487-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238699",
        "row": "[\"P10767-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238700",
        "row": "[\"Q92731-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238701",
        "row": "[\"Q99075-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238702",
        "row": "[\"O95750-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238703",
        "row": "[\"O14944-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238704",
        "row": "[\"Q06124-2\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238705",
        "row": "[\"P21781-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238706",
        "row": "[\"P49771-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238707",
        "row": "[\"P03372-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238708",
        "row": "[\"P42338-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238709",
        "row": "[\"P42336-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238710",
        "row": "[\"O14511-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238711",
        "row": "[\"P63000-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238712",
        "row": "[\"Q86Z14-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238713",
        "row": "[\"Q9HCT0-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238714",
        "row": "[\"Q9UQC2-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238715",
        "row": "[\"P00533-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238716",
        "row": "[\"P05230-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238717",
        "row": "[\"Q13480-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238718",
        "row": "[\"P15153-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238719",
        "row": "[\"P01133-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238720",
        "row": "[\"P01135-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238721",
        "row": "[\"P09038-4\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238722",
        "row": "[\"P16234-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238723",
        "row": "[\"P08620-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238724",
        "row": "[\"P14210-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238725",
        "row": "[\"P01127-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238726",
        "row": "[\"P10721-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238727",
        "row": "[\"P35070-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238728",
        "row": "[\"Q8WU20-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238729",
        "row": "[\"Q9NP95-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238730",
        "row": "[\"P33681-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238731",
        "row": "[\"P42081-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238732",
        "row": "[\"O43320-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238733",
        "row": "[\"O00329-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238734",
        "row": "[\"P36888-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238735",
        "row": "[\"P56975-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238736",
        "row": "[\"Q6ZUJ8-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238737",
        "row": "[\"Q6PIZ9-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238738",
        "row": "[\"P15391-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238739",
        "row": "[\"P04626-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238740",
        "row": "[\"P84095-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238741",
        "row": "[\"P27986-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238742",
        "row": "[\"P09619-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238743",
        "row": "[\"Q02297-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238744",
        "row": "[\"O00459-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238745",
        "row": "[\"Q8WWG1-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238746",
        "row": "[\"P22455-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238747",
        "row": "[\"P06241-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238748",
        "row": "[\"P31371-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238749",
        "row": "[\"Q92569-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238750",
        "row": "[\"P06239-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238751",
        "row": "[\"P10747-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238752",
        "row": "[\"O43815-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238753",
        "row": "[\"P08581-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238754",
        "row": "[\"Q6UW88-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238755",
        "row": "[\"P35568-1\", \"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.\", \"Molecular cancer therapeutics\", \"2008 Jul\", \"Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C\", \"protein_xref_pubmed\", \"18606717\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238756",
        "row": "[\"P15498-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238757",
        "row": "[\"P15514-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238758",
        "row": "[\"O15520-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238759",
        "row": "[\"O76093-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238760",
        "row": "[\"P12931-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238761",
        "row": "[\"Q9Y4H2-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238762",
        "row": "[\"Q9GZV9-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238763",
        "row": "[\"P11487-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238764",
        "row": "[\"P10767-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238765",
        "row": "[\"Q92731-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238766",
        "row": "[\"Q99075-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238767",
        "row": "[\"O95750-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238768",
        "row": "[\"O14944-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238769",
        "row": "[\"Q06124-2\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238770",
        "row": "[\"P21781-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238771",
        "row": "[\"P49771-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238772",
        "row": "[\"P03372-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238773",
        "row": "[\"P42338-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238774",
        "row": "[\"P42336-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238775",
        "row": "[\"O14511-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238776",
        "row": "[\"P63000-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238777",
        "row": "[\"Q86Z14-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238778",
        "row": "[\"Q9HCT0-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238779",
        "row": "[\"Q9UQC2-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238780",
        "row": "[\"P00533-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238781",
        "row": "[\"P05230-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238782",
        "row": "[\"Q13480-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238783",
        "row": "[\"P15153-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238784",
        "row": "[\"P01133-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238785",
        "row": "[\"P01135-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238786",
        "row": "[\"P09038-4\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238787",
        "row": "[\"P16234-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238788",
        "row": "[\"P08620-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238789",
        "row": "[\"P14210-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238790",
        "row": "[\"P01127-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238791",
        "row": "[\"P10721-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238792",
        "row": "[\"P35070-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238793",
        "row": "[\"Q8WU20-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238794",
        "row": "[\"Q9NP95-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238795",
        "row": "[\"P33681-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238796",
        "row": "[\"P42081-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238797",
        "row": "[\"O43320-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238798",
        "row": "[\"O00329-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238799",
        "row": "[\"P36888-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238800",
        "row": "[\"P56975-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238801",
        "row": "[\"Q6ZUJ8-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238802",
        "row": "[\"Q6PIZ9-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238803",
        "row": "[\"P15391-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238804",
        "row": "[\"P04626-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238805",
        "row": "[\"P84095-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238806",
        "row": "[\"P27986-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238807",
        "row": "[\"P09619-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238808",
        "row": "[\"Q02297-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238809",
        "row": "[\"O00459-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238810",
        "row": "[\"Q8WWG1-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238811",
        "row": "[\"P22455-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238812",
        "row": "[\"P06241-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238813",
        "row": "[\"P31371-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238814",
        "row": "[\"Q92569-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238815",
        "row": "[\"P06239-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238816",
        "row": "[\"P10747-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238817",
        "row": "[\"O43815-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238818",
        "row": "[\"P08581-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238819",
        "row": "[\"Q6UW88-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238820",
        "row": "[\"P35568-1\", \"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .\", \"Journal of medicinal chemistry\", \"2008 Sep 25\", \"Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ\", \"protein_xref_pubmed\", \"18754654\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238821",
        "row": "[\"P15498-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238822",
        "row": "[\"P15514-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238823",
        "row": "[\"O15520-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238824",
        "row": "[\"O76093-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238825",
        "row": "[\"P12931-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238826",
        "row": "[\"Q9Y4H2-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238827",
        "row": "[\"Q9GZV9-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238828",
        "row": "[\"P11487-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238829",
        "row": "[\"P10767-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238830",
        "row": "[\"Q92731-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238831",
        "row": "[\"Q99075-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238832",
        "row": "[\"O95750-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238833",
        "row": "[\"O14944-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238834",
        "row": "[\"Q06124-2\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238835",
        "row": "[\"P21781-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238836",
        "row": "[\"P49771-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238837",
        "row": "[\"P03372-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238838",
        "row": "[\"P42338-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238839",
        "row": "[\"P42336-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238840",
        "row": "[\"O14511-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238841",
        "row": "[\"P63000-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238842",
        "row": "[\"Q86Z14-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238843",
        "row": "[\"Q9HCT0-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238844",
        "row": "[\"Q9UQC2-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238845",
        "row": "[\"P00533-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238846",
        "row": "[\"P05230-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238847",
        "row": "[\"Q13480-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238848",
        "row": "[\"P15153-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238849",
        "row": "[\"P01133-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238850",
        "row": "[\"P01135-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238851",
        "row": "[\"P09038-4\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238852",
        "row": "[\"P16234-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238853",
        "row": "[\"P08620-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238854",
        "row": "[\"P14210-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238855",
        "row": "[\"P01127-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238856",
        "row": "[\"P10721-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238857",
        "row": "[\"P35070-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238858",
        "row": "[\"Q8WU20-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238859",
        "row": "[\"Q9NP95-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238860",
        "row": "[\"P33681-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238861",
        "row": "[\"P42081-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238862",
        "row": "[\"O43320-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238863",
        "row": "[\"O00329-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238864",
        "row": "[\"P36888-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238865",
        "row": "[\"P56975-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238866",
        "row": "[\"Q6ZUJ8-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238867",
        "row": "[\"Q6PIZ9-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238868",
        "row": "[\"P15391-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238869",
        "row": "[\"P04626-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238870",
        "row": "[\"P84095-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238871",
        "row": "[\"P27986-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238872",
        "row": "[\"P09619-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238873",
        "row": "[\"Q02297-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238874",
        "row": "[\"O00459-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238875",
        "row": "[\"Q8WWG1-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238876",
        "row": "[\"P22455-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238877",
        "row": "[\"P06241-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238878",
        "row": "[\"P31371-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238879",
        "row": "[\"Q92569-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238880",
        "row": "[\"P06239-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238881",
        "row": "[\"P10747-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238882",
        "row": "[\"O43815-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238883",
        "row": "[\"P08581-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238884",
        "row": "[\"Q6UW88-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238885",
        "row": "[\"P35568-1\", \"NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.\", \"Cancer research\", \"2008 Oct 1\", \"Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J\", \"protein_xref_pubmed\", \"18829560\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238886",
        "row": "[\"P15498-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238887",
        "row": "[\"P15514-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238888",
        "row": "[\"O15520-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238889",
        "row": "[\"O76093-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238890",
        "row": "[\"P12931-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238891",
        "row": "[\"Q9Y4H2-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238892",
        "row": "[\"Q9GZV9-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238893",
        "row": "[\"P11487-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238894",
        "row": "[\"P10767-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238895",
        "row": "[\"Q92731-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238896",
        "row": "[\"O95750-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238897",
        "row": "[\"Q06124-2\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238898",
        "row": "[\"P21781-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238899",
        "row": "[\"P49771-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238900",
        "row": "[\"P03372-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238901",
        "row": "[\"P42338-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238902",
        "row": "[\"P63000-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238903",
        "row": "[\"Q86Z14-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238904",
        "row": "[\"Q9HCT0-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238905",
        "row": "[\"Q9UQC2-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238906",
        "row": "[\"P05230-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238907",
        "row": "[\"P15153-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238908",
        "row": "[\"P01135-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238909",
        "row": "[\"P09038-4\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238910",
        "row": "[\"P16234-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238911",
        "row": "[\"P08620-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238912",
        "row": "[\"P14210-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238913",
        "row": "[\"P01127-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238914",
        "row": "[\"P10721-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238915",
        "row": "[\"Q8WU20-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238916",
        "row": "[\"Q9NP95-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238917",
        "row": "[\"P33681-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238918",
        "row": "[\"P42081-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238919",
        "row": "[\"O43320-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238920",
        "row": "[\"O00329-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238921",
        "row": "[\"P36888-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238922",
        "row": "[\"Q6ZUJ8-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238923",
        "row": "[\"Q6PIZ9-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238924",
        "row": "[\"P15391-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238925",
        "row": "[\"P84095-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238926",
        "row": "[\"P09619-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238927",
        "row": "[\"O00459-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238928",
        "row": "[\"P22455-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238929",
        "row": "[\"P06241-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238930",
        "row": "[\"P31371-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238931",
        "row": "[\"Q92569-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238932",
        "row": "[\"P06239-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238933",
        "row": "[\"P10747-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238934",
        "row": "[\"O43815-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238935",
        "row": "[\"P08581-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238936",
        "row": "[\"Q6UW88-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238937",
        "row": "[\"P35568-1\", \"Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.\", \"Cancer cell\", \"2009 May 5\", \"Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX\", \"protein_xref_pubmed\", \"19411071\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238938",
        "row": "[\"P15498-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238939",
        "row": "[\"P15514-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238940",
        "row": "[\"O15520-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238941",
        "row": "[\"O76093-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238942",
        "row": "[\"P12931-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238943",
        "row": "[\"Q9Y4H2-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238944",
        "row": "[\"Q9GZV9-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238945",
        "row": "[\"P11487-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238946",
        "row": "[\"P10767-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238947",
        "row": "[\"Q92731-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238948",
        "row": "[\"Q99075-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238949",
        "row": "[\"O95750-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238950",
        "row": "[\"O14944-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238951",
        "row": "[\"Q06124-2\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238952",
        "row": "[\"P21781-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238953",
        "row": "[\"P49771-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238954",
        "row": "[\"P03372-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238955",
        "row": "[\"P42338-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238956",
        "row": "[\"P42336-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238957",
        "row": "[\"O14511-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238958",
        "row": "[\"P63000-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238959",
        "row": "[\"Q86Z14-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238960",
        "row": "[\"Q9HCT0-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238961",
        "row": "[\"Q9UQC2-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238962",
        "row": "[\"P00533-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238963",
        "row": "[\"P05230-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238964",
        "row": "[\"Q13480-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238965",
        "row": "[\"P15153-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238966",
        "row": "[\"P01133-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238967",
        "row": "[\"P01135-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238968",
        "row": "[\"P09038-4\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238969",
        "row": "[\"P16234-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238970",
        "row": "[\"P08620-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238971",
        "row": "[\"P14210-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238972",
        "row": "[\"P01127-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238973",
        "row": "[\"P10721-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238974",
        "row": "[\"P35070-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238975",
        "row": "[\"Q8WU20-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238976",
        "row": "[\"Q9NP95-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238977",
        "row": "[\"P33681-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238978",
        "row": "[\"P42081-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238979",
        "row": "[\"O43320-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238980",
        "row": "[\"O00329-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238981",
        "row": "[\"P36888-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238982",
        "row": "[\"P56975-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238983",
        "row": "[\"Q6ZUJ8-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238984",
        "row": "[\"Q6PIZ9-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238985",
        "row": "[\"P15391-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238986",
        "row": "[\"P04626-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238987",
        "row": "[\"P84095-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238988",
        "row": "[\"P27986-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238989",
        "row": "[\"P09619-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238990",
        "row": "[\"Q02297-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238991",
        "row": "[\"O00459-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238992",
        "row": "[\"Q8WWG1-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238993",
        "row": "[\"P22455-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238994",
        "row": "[\"P06241-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238995",
        "row": "[\"P31371-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238996",
        "row": "[\"Q92569-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238997",
        "row": "[\"P06239-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238998",
        "row": "[\"P10747-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_238999",
        "row": "[\"O43815-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    },
    {
        "recordid": "GLY_000310_1_239000",
        "row": "[\"P08581-1\", \"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.\", \"Blood\", \"2010 Sep 23\", \"Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ\", \"protein_xref_pubmed\", \"20522708\", \"protein_xref_reactome\", \"R-HSA-2219530\"]"
    }
]